Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation

REFERENCES

• Alexandropoulos, K., and D. Baltimore. 1996. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin. Genes Dev. 10: 1341–1355.
   PubMed Web of Science ®Google Scholar
• Barila, D., and G. Superti-Furga. 1998. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18: 280–282.
   PubMed Web of Science ®Google Scholar
• Boyle, W. J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201: 110–149.
   PubMed Web of Science ®Google Scholar
• Brasher, B. B., and R. A. Van Etten. 2000. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275: 35631–35637.
   PubMed Web of Science ®Google Scholar
• Cao, C., X. Ren, S. Kharbanda, A. Koleske, K. V. Prasad, and D. Kufe. 2001. The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress. J. Biol. Chem. 276: 11465–11468.
   PubMedGoogle Scholar
• Cazzaniga, G., S. Tosi, A. Aloisi, G. Giudici, M. Daniotti, P. Pioltelli, L. Kearney, and A. Biondi. 1999. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 94: 4370–4373.
   PubMed Web of Science ®Google Scholar
• Cooper, J. A., B. M. Sefton, and T. Hunter. 1983. Detection and quantification of phosphotyrosine in proteins. Methods Enzymol. 99: 387–402.
   PubMed Web of Science ®Google Scholar
• Dorey, K., J. R. Engen, J. Kretzschmar, M. Wilm, G. Neubauer, T. Schindler, and G. Superti-Furga. 2001. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 20: 8075–8084.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville, and M. Talpaz. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038–1042.
   PubMed Web of Science ®Google Scholar
• Franz, W. M., P. Berger, and J. Y. Wang. 1989. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8: 137–147.
   PubMed Web of Science ®Google Scholar
• Furstoss, O., K. Dorey, V. Simon, D. Barila, G. Superti-Furga, and S. Roche. 2002. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 21: 514–524.
   PubMedGoogle Scholar
• Iijima, Y., T. Ito, T. Oikawa, M. Eguchi, M. Eguchi-Ishimae, N. Kamada, K. Kishi, S. Asano, Y. Sakaki, and Y. Sato. 2000. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 95: 2126–2131.
   PubMed Web of Science ®Google Scholar
• Jackson, P., and D. Baltimore. 1989. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8: 449–456.
   PubMed Web of Science ®Google Scholar
• Kharbanda, S., R. Ren, P. Pandey, T. D. Shafman, S. M. Feller, R. R. Weichselbaum, and D. W. Kufe. 1995. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785–788.
   PubMed Web of Science ®Google Scholar
• Koleske, A. J., A. M. Gifford, M. L. Scott, M. Nee, R. T. Bronson, K. A. Miczek, and D. Baltimore. 1998. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21: 1259–1272.
   PubMed Web of Science ®Google Scholar
• Kraker, A. J., B. G. Hartl, A. M. Amar, M. R. Barvian, H. D. Showalter, and C. W. Moore. 2000. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60: 885–898.
   PubMed Web of Science ®Google Scholar
• Kruh, G. D., R. Perego, T. Miki, and S. A. Aaronson. 1990. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc. Natl. Acad. Sci. USA 87: 5802–5806.
   PubMed Web of Science ®Google Scholar
• Lewis, J. M., R. Baskaran, S. Taagepera, M. A. Schwartz, and J. Y. Wang. 1996. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc. Natl. Acad. Sci. USA 93: 15174–15179.
   PubMed Web of Science ®Google Scholar
• Matsuda, M., B. J. Mayer, Y. Fukui, and H. Hanafusa. 1990. Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins. Science 248: 1537–1539.
   PubMedGoogle Scholar
• McWhirter, J. R., D. L. Galasso, and J. Y. Wang. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13: 7587–7595.
   PubMed Web of Science ®Google Scholar
• Miao, Y. J., and J. Y. Wang. 1996. Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase. J. Biol. Chem. 271: 22823–22830.
   PubMedGoogle Scholar
• Moarefi, I., M. LaFevre-Bernt, F. Sicheri, M. Huse, C. H. Lee, J. Kuriyan, and W. T. Miller. 1997. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385: 650–653.
   PubMed Web of Science ®Google Scholar
• Nagar, B., W. G. Bornmann, P. Pellicena, T. Schindler, D. R. Veach, W. T. Miller, B. Clarkson, and J. Kuriyan. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62: 4236–4243.
   PubMed Web of Science ®Google Scholar
• Piwnica-Worms, H., K. B. Saunders, T. M. Roberts, A. E. Smith, and S. H. Cheng. 1987. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell 49: 75–82.
   PubMed Web of Science ®Google Scholar
• Plattner, R., L. Kadlec, K. A. DeMali, A. Kazlauskas, and A. M. Pendergast. 1999. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13: 2400–2411.
   PubMed Web of Science ®Google Scholar
• Pluk, H., K. Dorey, and G. Superti-Furga. 2002. Autoinhibition of c-Abl. Cell 108: 247–259.
   PubMed Web of Science ®Google Scholar
• Schindler, T., W. Bornmann, P. Pellicena, W. T. Miller, B. Clarkson, and J. Kuriyan. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938–1942.
   PubMed Web of Science ®Google Scholar
• Schindler, T., F. Sicheri, A. Pico, A. Gazit, A. Levitzki, and J. Kuriyan. 1999. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3: 639–648.
   PubMed Web of Science ®Google Scholar
• Sicheri, F., I. Moarefi, and J. Kuriyan. 1997. Crystal structure of the Src family tyrosine kinase Hck. Nature 385: 602–609.
   PubMed Web of Science ®Google Scholar
• Sun, X., P. Majumder, H. Shioya, F. Wu, S. Kumar, R. Weichselbaum, S. Kharbanda, and D. Kufe. 2000. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem. 275: 17237–17240.
   PubMed Web of Science ®Google Scholar
• Superti-Furga, G., S. Fumagalli, M. Koegl, S. A. Courtneidge, and G. Draetta. 1993. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 12: 2625–2634.
   PubMed Web of Science ®Google Scholar
• Thomas, S. M., and J. S. Brugge. 1997. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13: 513–609.
   PubMed Web of Science ®Google Scholar
• Wang, Y., A. L. Miller, M. S. Mooseker, and A. J. Koleske. 2001. The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin. Proc. Natl. Acad. Sci. USA 98: 14865–14870.
   PubMedGoogle Scholar
• Wen, S. T., and R. A. Van Etten. 1997. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11: 2456–2467.
   PubMed Web of Science ®Google Scholar
• Xu, W., A. Doshi, M. Lei, M. J. Eck, and S. C. Harrison. 1999. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3: 629–638.
   PubMed Web of Science ®Google Scholar
• Xu, W., S. C. Harrison, and M. J. Eck. 1997. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385: 595–602.
   PubMed Web of Science ®Google Scholar
• Yamaguchi, H., and W. A. Hendrickson. 1996. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384: 484–489.
   PubMed Web of Science ®Google Scholar